TECNOTREE
Tecnotree, a leading global Digital Transformation Partner for the Telecom Industry, is the first non-telco to be certified for real-world open API implementation on the leader board for TM Forum Open API Conformance. The certifications were carried out jointly with MTN in live operations within the MTN environment and demonstrated the successful implementation of Open APIs in commercial products and real-world deployments. Alignment to industry standards and best practices have been a part of Tecnotree’s DNA and its Digital Transformation strategy and proves Tecnotree’s commitment to industry standards, customers, and partner ecosystems. This landmark achievement makes Tecnotree the first Digital Platform Company among a list of CSPs like Verizon, Bell, and JIO, for certified real-world open API implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005054/en/
Tecnotree is the First Digital Platform Company in the World to be Certified for Real-World Open API Implementation by TM Forum (Photo: Business Wire)
Tecnotree’s Digital Platform powered with Open APIs using Open Digital Architecture enables quick and flexible integration to transform telecom business and operation models that extends beyond connectivity to monetise platform-based business models and partner ecosystems across verticals.
“We congratulate Tecnotree for being the first non-telco to achieve real-world certification for Open APIs deployed in live operation with MTN,” commented George Glass, CTO of TM Forum. “This is a path-breaking move by a software solutions provider and reaffirms Tecnotree’s commitment to open standards and their investment in next-generation product modernization. Tecnotree has been a great supporter of TM Forum’s work and is demonstrating the business value of Open APIs in enabling digital transformation for their customers.”
Monzer Ali, CTIO of MTN Uganda commented, “MTN and Tecnotree have been at the forefront of aligning with TM Forum frameworks (TAM, SID, Open APIs, eTOM) in our digital transformation journey. Tecnotree Digital BSS Suite is TMF ODA’s component-based architecture and is fully cloud-enabled, having an orchestration of micro-services capability that allows us to provide not only connectivity services for our subscribers but also digital services from adjacent industries, thus truly helping us monetize the power of 5G.”
Padma Ravichander, CEO of Tecnotree Corporation said, “This recognition is a true testimony of our journey as a pioneer in TM Forum’s Open API certification. Real-world Open API conformance and certification for Tecnotree is our commitment towards our customers to help them unlock and monetize the power of 5G with a range of digital products and services. These solutions can be provided to their customers, with seamless connectivity, speed, agility, and interoperability, on our Tecnotree Digital BSS platform. Our platform further enables operators to partner with the industry’s best ecosystem players to monetize B2B and B2B2X non-telco offerings by leveraging 5G for new digital multi-experiences.”
TM Forum Open API suite was developed in collaboration to drive IT agility, and digital business transformation. The certification recognizes how well your industry solutions, business processes, or open APIs align within the industry standards. They unlock a range of growth opportunities by providing exposure to new products and services while reducing cost and time to market. A large number of major global operators and vendors use the TM Forum Open API conformance, and the APIs are deployed all over the world.
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is the first company in the world to be Platinum Certified by TM Forum Open API standards, and our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree digital platform products and services today serve over 1 Billion Subscribers globally in over 70 countries. Tecnotree is listed on Helsinki Nasdaq (TEM1V).
For more information, please visit www.tecnotree.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005054/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom